Developer of artificial intelligence software for medical imaging diagnostic analysis. This technology integrates with existing radiology hardware to identify abnormalities...
Total Rounds: 9 Qure.ai
| S.No. | Date | Round Name | Amount | TTM Revenue | Investors & Facilitators |
|---|---|---|---|---|---|
| 1. | Jan 22, 2026 | Grant (prize money) | - | ₹300 Cr | Inst: Gates |
| 2. | Sep 23, 2024 | Series D | ₹543 Cr | ₹172 Cr | Inst: 360 One, Merck Global Health Innovation Fund, Kae Capital, Novo Holdings, HealthQuad, TEAMFund, Lightspeed Venture Partners Facil: DC Advisory |
| 3. | May 22, 2024 | Series C | ₹14 Cr | ₹160 Cr | Inst: Merck Global Health Innovation Fund |
| 4. | Jun 28, 2023 | Grant (prize money) | - | ₹107 Cr | Inst: C-CAMP |
| 5. | 2023 | Grant (prize money) | - | ₹44 Cr | Inst: ACT Grants |
| 6. | Apr 29, 2022 | Series C | - | ₹44 Cr | Inst: Merck, Merck Sharp & Dohme |
| 7. | Mar 29, 2022 | Series C | ₹303 Cr | ₹39 Cr | Inst: MassMutual Ventures, HealthQuad, Novo Holdings, Merck, Akshat Greentech, TEAMFund Facil: Lincoln International |
| 8. | Feb 23, 2022 | Grant (prize money) | ₹32 Cr | ₹37 Cr | Inst: SBRI Healthcare |
| 9. | Feb 24, 2020 | Series B | ₹115 Cr | ₹1.3 Cr | Inst: MassMutual Ventures, Redwood Trust, Peak XV Partners Angel: Pranay, Rasesh, Don, Ajoy, Sankaranarayanan, Rajeswari, Parameswaran, Naushad, Sandeep, Natwar, Chiranjiv, Swetha, Gangaprasad, Bunty, Neema, Aparna, Satish, Reshma, Ammar, Hitiksha, Avinash, Divyaparvathy, Annu, John, Satish, Srikanth, Tarun, Ankit, Rohit, Sasank, Prashant |
| Detailed Income Statement | FY 24-25 (in Cr) |
|---|---|
| 190.4 | |
| 279.2 | |
| Total profit before exceptional items, extraordinary items and tax | (88.8) |
| Total profit before tax | (88.8) |
| 1.6 | |
| Total profit (loss) for period from continuing operations | (90.4) |
| Total profit (loss) for period | (90.4) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 24-25 (in Cr) |
|---|---|
| 553.5 | |
| 553.5 |
| Detailed Cash Flow Statement | FY 24-25 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (96.7) |
| Net cash from / (used in) investing activities | (225.8) |
| Net cash from / (used) in financing activities | 289.8 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | (32.6) |
| Effect of exchange rate changes on cash and cash equivalents | 0.4 |
| Net increase / (decrease) in cash and cash equivalents | (32.3) |
| Cash and cash equivalents at the beginning of the year | 67.7 |
| Cash and cash equivalents at the end of the year | 35.4 |
| Detailed Income Statement | FY 23-24 (in Cr) |
|---|---|
| 154.0 | |
| 200.7 | |
| Total profit before exceptional items, extraordinary items and tax | (46.7) |
| Total profit before tax | (46.7) |
| 1.2 | |
| Total profit (loss) for period from continuing operations | (47.9) |
| Total profit (loss) for period | (47.9) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 23-24 (in Cr) |
|---|---|
| 335.5 | |
| 335.5 |
| Detailed Cash Flow Statement | FY 23-24 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (128.7) |
| Net cash from / (used in) investing activities | 113.7 |
| Net cash from / (used) in financing activities | 0.5 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | (14.5) |
| Effect of exchange rate changes on cash and cash equivalents | (0.5) |
| Net increase / (decrease) in cash and cash equivalents | (15.0) |
| Cash and cash equivalents at the beginning of the year | 82.7 |
| Cash and cash equivalents at the end of the year | 67.7 |
| Detailed Income Statement | FY 22-23 (in Cr) |
|---|---|
| 91.3 | |
| 169.1 | |
| Total profit before exceptional items, extraordinary items and tax | (77.8) |
| Total profit before tax | (77.8) |
| 0.1 | |
| Total profit (loss) for period from continuing operations | (77.8) |
| Total profit (loss) for period | (77.8) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 22-23 (in Cr) |
|---|---|
| 364.6 | |
| 364.6 |
| Detailed Cash Flow Statement | FY 22-23 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (60.0) |
| Net cash from / (used in) investing activities | (173.1) |
| Net cash from / (used) in financing activities | 299.4 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | 66.3 |
| Effect of exchange rate changes on cash and cash equivalents | 0.4 |
| Net increase / (decrease) in cash and cash equivalents | 66.7 |
| Cash and cash equivalents at the beginning of the year | 15.9 |
| Cash and cash equivalents at the end of the year | 82.7 |
| Detailed Income Statement | FY 21-22 (in Cr) |
|---|---|
| 39.3 | |
| 62.8 | |
| Total profit before exceptional items, extraordinary items and tax | (23.4) |
| Total profit before tax | (23.4) |
| 0.5 | |
| Total profit (loss) for period from continuing operations | (24.0) |
| Total profit (loss) for period | (24.0) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 21-22 (in Cr) |
|---|---|
| 91.7 | |
| 91.7 |
| Detailed Cash Flow Statement | FY 21-22 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (24.3) |
| Net cash from / (used in) investing activities | (14.0) |
| Net cash from / (used) in financing activities | 0.5 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | (37.8) |
| Effect of exchange rate changes on cash and cash equivalents | (0.0) |
| Net increase / (decrease) in cash and cash equivalents | (37.9) |
| Cash and cash equivalents at the beginning of the year | 53.8 |
| Cash and cash equivalents at the end of the year | 15.9 |
| Detailed Income Statement | FY 20-21 (in Cr) |
|---|---|
| 12.4 | |
| 32.3 | |
| Total profit before exceptional items, extraordinary items and tax | (20.0) |
| Total profit before tax | (20.0) |
| 0.1 | |
| Total profit (loss) for period from continuing operations | (20.1) |
| Total profit (loss) for period | (20.1) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 20-21 (in Cr) |
|---|---|
| 86.2 | |
| 86.2 |
| Detailed Cash Flow Statement | FY 20-21 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (39.1) |
| Net cash from / (used in) investing activities | (4.9) |
| Net cash from / (used) in financing activities | 22.4 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | (21.6) |
| Effect of exchange rate changes on cash and cash equivalents | 0.1 |
| Net increase / (decrease) in cash and cash equivalents | (21.5) |
| Cash and cash equivalents at the beginning of the year | 75.3 |
| Cash and cash equivalents at the end of the year | 53.8 |
| Detailed Income Statement | FY 19-20 (in Cr) |
|---|---|
| 1.3 | |
| 29.2 | |
| Total profit before exceptional items, extraordinary items and tax | (27.9) |
| Total profit before tax | (27.9) |
| 0 | |
| Total profit (loss) for period from continuing operations | (27.9) |
| Total profit (loss) for period | (27.9) |
| Basic earning per equity share | (0.0) |
| Diluted earnings per equity share | (0.0) |
| Detailed Balance Sheet | FY 19-20 (in Cr) |
|---|---|
| 99.0 | |
| 99.0 |
| Detailed Cash Flow Statement | FY 19-20 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (7.6) |
| Net cash from / (used in) investing activities | (10.6) |
| Net cash from / (used) in financing activities | 93.5 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | 75.3 |
| Effect of exchange rate changes on cash and cash equivalents | (0.4) |
| Net increase / (decrease) in cash and cash equivalents | 74.9 |
| Cash and cash equivalents at the beginning of the year | 0.4 |
| Cash and cash equivalents at the end of the year | 75.3 |
| Detailed Income Statement | FY 18-19 (in Cr) |
|---|---|
| 0.8 | |
| 11.4 | |
| Total profit before exceptional items, extraordinary items and tax | (10.6) |
| Total profit before tax | (10.6) |
| Total tax expense | 0 |
| Total profit (loss) for period from continuing operations | (10.6) |
| Total profit (loss) for period | (10.6) |
| Detailed Balance Sheet | FY 18-19 (in Cr) |
|---|---|
| 11.7 | |
| 11.7 |
| Detailed Cash Flow Statement | FY 18-19 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | (4.2) |
| Net cash from / (used in) investing activities | (5.2) |
| Net cash from / (used) in financing activities | 9.7 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | 0.4 |
| Net increase / (decrease) in cash and cash equivalents | 0.4 |
| Cash and cash equivalents at the beginning of the year | 0.0 |
| Cash and cash equivalents at the end of the year | 0.4 |
| Detailed Income Statement | FY 17-18 (in Cr) |
|---|---|
| 0.0 | |
| 0.0 | |
| Total profit before exceptional items, extraordinary items and tax | (0.0) |
| Total profit before tax | (0.0) |
| 0 | |
| Total profit (loss) for period from continuing operations | (0.0) |
| Total profit (loss) for period | (0.0) |
| Detailed Balance Sheet | FY 17-18 (in Cr) |
|---|---|
| 16.2 | |
| 16.2 |
| Detailed Cash Flow Statement | FY 17-18 (in Cr) |
|---|---|
| Net cash from / (used in) operating activities | 1.2 |
| Net cash from / (used in) investing activities | (16.2) |
| Net cash from / (used) in financing activities | 14.9 |
| Net increase / (decrease) in cash and cash equivalents before effect of exchange rate changes | (0.1) |
| Net increase / (decrease) in cash and cash equivalents | (0.1) |
| Cash and cash equivalents at the beginning of the year | 0.1 |
| Cash and cash equivalents at the end of the year | 0.0 |
| Detailed Income Statement | FY 16-17 (in Cr) |
|---|---|
| 0 | |
| 0.0 | |
| Profit/(Loss) before tax | (0.0) |
| Total tax expense | 0 |
| Profit/(Loss) for the year | (0.0) |
| Detailed Balance Sheet | FY 16-17 (in Cr) |
|---|---|
| 0.1 | |
| 0.1 |
| Detailed Cash Flow Statement | FY 16-17 (in Cr) |
|---|---|
| Cash flow from Operating activities | 0 |
| Net cash from/(used in) Operating activities | 0 |
| Cash flow from Investing activities | 0 |
| Net cash from/(used in) Investing activities | 0 |
| Cash flow from Financing activities | 0.1 |
| Net cash from/(used) in Financing activities | 0.1 |
| Net increase /(Decrease) in cash and cash equivalents before Effect rate changes | 0.1 |
| Effect of rate changes on cash and cash equivalents | 0 |
| Net increase /(Decrease) in cash and cash equivalents | 0.1 |
| Cash and cash equivalents at the beginning of the year | 0 |
| Cash and cash equivalents at the end of the year | 0.1 |
As of Jan 14, 2026 • Qure.ai
| Shareholder | Category | Shares (Mn) | % Holding |
|---|---|---|---|
| Aditya Jaiswal | Other | 0.05M | 100.00% |